Suparnostic

Last updated

suPARnostic is a simplified double monoclonal antibody sandwich enzyme-linked immunosorbent assay (ELISA) that measures the amount of soluble urokinase plasminogen activator receptor (suPAR) in blood. [1] Elevated plasma suPAR levels have been observed in various infectious, inflammatory and autoimmune diseases. [2] suPAR concentration positively correlates to the activation level of the immune system. suPARnostic can be used as a prognostic tool [3] to determine the severity of a disease within a patient, but is not used as a reliable diagnostic tool, as it can detect the severity of the immune response in a patient, but does not reveal the specific disease from which the patient may be suffering. Recently, increase suPAR levels were shown to be associated with increased risk of systemic inflammatory response syndrome (SIRS)/sepsis, cardiovascular disease, type 2 diabetes, infectious diseases, HIV, [4] cancer [5] tuberculosis, [3] malaria, [6] bacterial and viral CNS infections, [7] rheumatoid arthritis, [8] multiple sclerosis [3] and mortality in the general population.

Contents

Performing the suPARnostic ELISA

Performing the suPARnostic ELISA requires two antibodies with high specificity for suPAR. The blood plasma sample from the patient that contains an unknown amount of suPAR is immobilized on the microwells on the clear microtiter plate and a detection antibody forms a complex with suPAR. Between each step the plate is rinsed with a wash buffer to dispose of any proteins that do not specifically bind to any of the wells on the plate. After the final wash step, the plate is developed by adding the TMB substrate to produce a visible signal, which indicates the quantity of suPAR in the sample. The measured absorbance can, based on the values from the standard curve, be converted to the concentration (ng/mL) of suPAR in the sample. This level can then suggest whether or not the patient is experiencing challenges to their immune system. [3]

Principles

The suPARnostic ELISA is a simplified double monoclonal antibody sandwich assay that measures the level of suPAR and suPARII-III in the body . The suPARnostic ELISA utilizes monoclonal mouse and rat antibodies against human suPAR. [9]

The advantages of using monoclonal antibodies compared to using polyclonal antibodies includes: High homogeneity, absence of nonspecific antibodies and no batch-to-batch or lot-to-lot variability. This results in a very robust and reliable assay. [3]

A 'sandwich' is formed of solid-phase antibody, suPAR and peroxidase-conjugated antibody. The concentration (ng/mL plasma) of suPAR in the patient sample is determined via interpolation, based on a calibration curve prepared from seven suPAR standards. Recombinant suPAR standards are calibrated against healthy human blood donor samples. Absorbance is measured using a microtiter plate reader, at 450 nm with a 650 nm reference filter. Measurement of suPAR levels from blood samples provides greater accuracy and precision than measurement from urine or cerebral spinal fluid. suPAR level is not changed by transient illness such as cold. It also remains stable after a blood sample is taken despite storage. [10] [11]

suPARnostic measurements between 0.1 and 4.0 ng/mL suggest that a patient is healthy, with no challenges to their immune system and no signs or symptoms of an opportunistic infection or inflammation; the average level among the population is 3.4 ng/mL. However, a patient's immune system can be considered 'negatively activated' at suPAR levels above 4.0 and up to 6.0 ng/mL, indicating a potential infection or high level of inflammation. In this case, a patient's health is likely to worsen and he or she should be referred for further testing. suPARnostic measurements from 6.0 ng/mL to double digit levels can indicate a serious illness that is progressing rapidly to a critical situation. Patients in the intensive care unit average a level of 10.0 ng/mL. There is no difference in suPAR levels intrinsic to various races; however, the scale varies for male and female. [9] [11]

There are two suPARnostic tests available. The suPARnostic Standard ELISA (Code No. A001) is for research use and large trials, one batch consisting of 41 samples in doublets. The suPARnostic Flex ELISA (Code No. A002) has been developed for clinical applications consisting of 93 samples, is modular and flexible, and gives fully quantitative results in 2 hours. [11]

Practical Considerations

The suPARnostic kit has a refrigerated shelf life of several years and when frozen, may be kept for longer. The kit should sit at room temperature for half an hour before use but it may be held at room temperature for as long as three to four hours. [12] The suPARnostic Flex ELISA (Code No. A002) is able to provide fully quantitative results in 2 hours. [13] suPARnostic is run as large, batch test with up to 41 samples in doublets for research purposes or 93 samples for clinical use at one time. [11]

Although suPARnostic currently does not have FDA approval, it is CE/IVD marked for distribution throughout Europe. [11] suPAR is a prognostic test to indicate general health, and it cannot be used as a diagnostic tool to suggest a particular illness. [9] suPAR cannot be used in the detection of brain tumors because the suPAR molecule cannot migrate through the blood brain barrier. [2]

Related Research Articles

<span class="mw-page-title-main">Antibody</span> Protein(s) forming a major part of an organisms immune system

An antibody (Ab) or immunoglobulin (Ig) is a large, Y-shaped protein belonging to the immunoglobulin superfamily which is used by the immune system to identify and neutralize antigens such as bacteria and viruses, including those that cause disease. Antibodies can recognize virtually any size antigen with diverse chemical compositions from molecules. Each antibody recognizes one or more specific antigens. Antigen literally means "antibody generator", as it is the presence of an antigen that drives the formation of an antigen-specific antibody. Each tip of the "Y" of an antibody contains a paratope that specifically binds to one particular epitope on an antigen, allowing the two molecules to bind together with precision. Using this mechanism, antibodies can effectively "tag" a microbe or an infected cell for attack by other parts of the immune system, or can neutralize it directly.

Fibrinolysis is a process that prevents blood clots from growing and becoming problematic. Primary fibrinolysis is a normal body process, while secondary fibrinolysis is the breakdown of clots due to a medicine, a medical disorder, or some other cause.

<span class="mw-page-title-main">Immunosuppressive drug</span> Drug that inhibits activity of immune system

Immunosuppressive drugs, also known as immunosuppressive agents, immunosuppressants and antirejection medications, are drugs that inhibit or prevent the activity of the immune system.

Humoral immunity is the aspect of immunity that is mediated by macromolecules – including secreted antibodies, complement proteins, and certain antimicrobial peptides – located in extracellular fluids. Humoral immunity is named so because it involves substances found in the humors, or body fluids. It contrasts with cell-mediated immunity. Humoral immunity is also referred to as antibody-mediated immunity.

In immunology, cytokine release syndrome (CRS) is a form of systemic inflammatory response syndrome (SIRS) that can be triggered by a variety of factors such as infections and certain drugs. It refers to cytokine storm syndromes (CSS) and occurs when large numbers of white blood cells are activated and release inflammatory cytokines, which in turn activate yet more white blood cells. CRS is also an adverse effect of some monoclonal antibody medications, as well as adoptive T-cell therapies. When occurring as a result of a medication, it is also known as an infusion reaction.

In immunology, antiserum is a blood serum containing antibodies that is used to spread passive immunity to many diseases via blood donation (plasmapheresis). For example, convalescent serum, passive antibody transfusion from a previous human survivor, used to be the only known effective treatment for ebola infection with a high success rate of 7 out of 8 patients surviving.

<span class="mw-page-title-main">Hybridoma technology</span> Method for producing lots of identical antibodies

Hybridoma technology is a method for producing large numbers of identical antibodies, also called monoclonal antibodies. This process starts by injecting a mouse with an antigen that provokes an immune response. A type of white blood cell, the B cell, produces antibodies that bind to the injected antigen. These antibody producing B-cells are then harvested from the mouse and, in turn, fused with immortal myeloma cancer cells, to produce a hybrid cell line called a hybridoma, which has both the antibody-producing ability of the B-cell and the longevity and reproductivity of the myeloma.

<span class="mw-page-title-main">Urokinase</span> Human protein

Urokinase, also known as urokinase-type plasminogen activator (uPA), is a serine protease present in humans and other animals. The human urokinase protein was discovered, but not named, by McFarlane and Pilling in 1947. Urokinase was originally isolated from human urine, and it is also present in the blood and in the extracellular matrix of many tissues. The primary physiological substrate of this enzyme is plasminogen, which is an inactive form (zymogen) of the serine protease plasmin. Activation of plasmin triggers a proteolytic cascade that, depending on the physiological environment, participates in thrombolysis or extracellular matrix degradation. This cascade had been involved in vascular diseases and cancer progression.

<span class="mw-page-title-main">Anakinra</span> Pharmaceutical drug

Anakinra, sold under the brand name Kineret, is a biopharmaceutical medication used to treat rheumatoid arthritis, cryopyrin-associated periodic syndromes, familial Mediterranean fever, and Still's disease. It is a slightly modified recombinant version of the human interleukin 1 receptor antagonist protein. It is marketed by Swedish Orphan Biovitrum. Anakinra is administered by subcutaneous injection.

<span class="mw-page-title-main">Plasminogen activator inhibitor-1</span> Human protein

Plasminogen activator inhibitor-1 (PAI-1) also known as endothelial plasminogen activator inhibitor is a protein that in humans is encoded by the SERPINE1 gene. Elevated PAI-1 is a risk factor for thrombosis and atherosclerosis.

<span class="mw-page-title-main">Plasminogen activator</span> Type of protein

Plasminogen activators are serine proteases that catalyze the activation of plasmin via proteolytic cleavage of its zymogen form plasminogen. Plasmin is an important factor in fibrinolysis, the breakdown of fibrin polymers formed during blood clotting. There are two main plasminogen activators: urokinase (uPA) and tissue plasminogen activator (tPA). Tissue plasminogen activators are used to treat medical conditions related to blood clotting including embolic or thrombotic stroke, myocardial infarction, and pulmonary embolism.

<span class="mw-page-title-main">Urokinase receptor</span> Mammalian protein found in Homo sapiens

The Urokinase receptor, also known as urokinase plasminogen activator surface receptor (uPAR) or CD87, is a protein encoded in humans by the PLAUR gene. It is a multidomain glycoprotein tethered to the cell membrane with a glycosylphosphotidylinositol (GPI) anchor. uPAR was originally identified as a saturable binding site for urokinase on the cell surface.

<span class="mw-page-title-main">Plasminogen activator inhibitor-2</span> Coagulation factor protein found in humans

Plasminogen activator inhibitor-2, a serine protease inhibitor of the serpin superfamily, is a coagulation factor that inactivates tissue plasminogen activator and urokinase. It is present in most cells, especially monocytes/macrophages. PAI-2 exists in two forms, a 60-kDa extracellular glycosylated form and a 43-kDa intracellular form.

<span class="mw-page-title-main">Monoclonal antibody therapy</span> Form of immunotherapy

Monoclonal antibodies (mAbs) have varied therapeutic uses. It is possible to create a mAb that binds specifically to almost any extracellular target, such as cell surface proteins and cytokines. They can be used to render their target ineffective, to induce a specific cell signal, to cause the immune system to attack specific cells, or to bring a drug to a specific cell type.

<span class="mw-page-title-main">Polyclonal B cell response</span> Immune response by adaptive immune system

Polyclonal B cell response is a natural mode of immune response exhibited by the adaptive immune system of mammals. It ensures that a single antigen is recognized and attacked through its overlapping parts, called epitopes, by multiple clones of B cell.

A neutralizing antibody (NAb) is an antibody that defends a cell from a pathogen or infectious particle by neutralizing any effect it has biologically. Neutralization renders the particle no longer infectious or pathogenic. Neutralizing antibodies are part of the humoral response of the adaptive immune system against viruses, bacteria and microbial toxin. By binding specifically to surface structures (antigen) on an infectious particle, neutralizing antibodies prevent the particle from interacting with its host cells it might infect and destroy.

Soluble urokinase plasminogen activator receptor (suPAR) is a protein and the soluble form of uPAR. uPAR is expressed mainly on immune cells, endothelial cells, and smooth muscle cells. uPAR is a membrane-bound receptor for uPA, also known as urokinase and Vitronectin. The soluble version of uPAR, called suPAR, results from the cleavage and membrane-bound uPAR during inflammation or immune activation. The suPAR concentration is positively correlated to the activation level of the immune system. Therefore, suPAR is a marker of disease severity and aggressiveness and is associated with morbidity and mortality in several acute and chronic diseases. suPAR levels have been observed to increase with age. suPAR is present in plasma, urine, blood, serum, and cerebrospinal fluid.

<span class="mw-page-title-main">Male accessory gland infection</span> Medical condition

Male accessory gland infection (MAGI) is a condition with signs of inflammation involving one or more sites in the male genital tract. Diagnosis is made according to parameters defined by the World Health Organization, and it is particularly made in relation to infectious or inflammatory causes of male infertility.

<span class="mw-page-title-main">Jochen Reiser</span> German nephrologist (born 1971)

Jochen Reiser is a physician-scientist and a healthcare leader. He is the President of the University of Texas Medical Branch (UTMB) and CEO of the UTMB Health System, which includes the oldest medical school and nursing school in Texas. As chief executive officer, he oversees the enterprise which includes multiple campuses, five health science colleges, the Galveston National Laboratory (BSL-4) and the Correctional Health Care Services for most of Texas.

<span class="mw-page-title-main">Serum B-cell maturation antigen</span> Cleaved form of B-cell maturation antigen

Serum B-cell maturation antigen (sBCMA) is the cleaved form of B-cell maturation antigen (BCMA), found at low levels in the serum of normal patients and generally elevated in patients with multiple myeloma (MM). Changes in sBCMA levels have been found to correlate with a MM patient’s clinical status in response to treatment.

References

  1. ↑ "Do You Know Your suPARnostic Level?". Virogates.com. 27 July 2009. Retrieved 12 November 2009.
  2. 1 2 suPAR: the molecular crystal ball. Thunø M, Macho B, Eugen-Olsen J. Dis Markers. 2009;27(3):157-72.
  3. 1 2 3 4 5 "What is suPAR?". virogates.com. 2020. Retrieved 7 October 2020.
  4. ↑ Schneider, U. V.; Nielsen, R. L.; Pedersen, C.; Eugen-Olsen, J. (2007). "The prognostic value of the suPARnostic® ELISA in HIV-1 infected individuals is not affected by uPAR promoter polymorphisms". BMC Infectious Diseases. 7: 134. doi: 10.1186/1471-2334-7-134 . PMC   2216028 . PMID   18021410.
  5. ↑ Rigolin, Gian Matteo et al. Soluble urokinase-type plasminogen activator receptor (suPAR) as an independent factor predicting worse prognosis and extra-bone marrow involvement in multiple myeloma patients. British Journal of Haematology. 120(60): 953–959. 18 March 2003.
  6. ↑ Ostrowski Sr, Ullum H, Goka BQ, Høyer-Hansen G, Obeng-Adjei G, Pedersen BK, Akanmori BD, Kurtzhals JA. 2005. Plasma concentrations of soluble urokinase-type plasminogen activator receptor are increased in patients with malaria and are associated with a poor clinical or a fatal outcome. J Infec Dis. 191(8):1331-41.
  7. ↑ Soluble urokinase receptor (uPAR, CD 87) is present in serum and cerebrospinal fluid in patients with neurologic diseases. Garcia-Monco JC, Coleman JL, Benach JL. 2002. Soluble urokinase receptor (uPAR, CD 87) is present in serum and cerebrospinal fluid in patients with neurologic diseases. J Neuroimmunol. 129(1-2):216-23.
  8. ↑ Pliyev BK, Menshikov MY. 2010. Release of the soluble urokinase-type plasminogen activator receptor (suPAR) by activated neutrophils in rheumatoid arthritis. Inflammation. 33(1):1-9.
  9. 1 2 3 ViroGates. "What is suPAR".
  10. ↑ suPARnostic Kit insert, (2008) 2nd Edition, 1-23
  11. 1 2 3 4 5 ViroGates. "SuPARnostic Products".
  12. ↑ "SuPARnostic by ViroGates".
  13. ↑ "suPARnostic® Products".
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.